IL-12 Pretreatments Enhance IFN-α-Induced Janus Kinase-STAT Signaling and Potentiate the Antitumor Effects of IFN-α in a Murine Model of Malignant Melanoma
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
IFN-α 2b (IFN-α) has been used to treat patients with metastatic malignant melanoma and patients rendered disease-free via surgery but at high risk for recurrence. We hypothesized that IL-12 pretreatments would result in endogenous IFN-γ production, and that this, in turn, would up-regulate levels of Janus kinase-STAT signaling intermediates and lead to increased expression of genes regulated by IFN-α. Treatment of PBMCs with IL-12 stimulated a significant and dose-dependent production of IFN-γ. Pretreatment of PBMCs and tumor cells with IFN-γ-containing supernatants from IL-12-stimulated PBMCs led to up-regulation of STAT1, STAT2, and IFN regulatory factor 9 (IRF9) and potentiated IFN-α-induced STAT signaling within PBMCs and tumor cells. These effects were abrogated by neutralization of IFN-γ in the PBMC supernatants with an anti-IFN-γ Ab. Pretreatment of HT144 melanoma cells and PBMCs with IFN-γ or IFN-γ-containing supernatants enhanced the actions of IFN-α at the transcriptional level, as measured by real-time RT PCR analysis of the IFN-stimulated gene 15. Experiments in wild-type C57BL/6 and IFN-γ receptor knockout (B6.129S7-Ifngrtm1Agt) mice demonstrated that a regimen of IL-12 pretreatment, followed by IFN-α, could cure mice of i.p. B16F1 melanoma tumors (p < 0.007), whereas mice treated with either agent alone or PBS succumbed to fatal tumor burden. However, this treatment regimen did not significantly prolong the survival of IFN-γ-deficient (B6.129S7-Ifngtm1Ts) mice compared with mice treated with IFN-α alone. These results suggest that the response to IFN-α immunotherapy can be significantly enhanced by IL-12 pretreatment, and this effect is dependent upon endogenous IFN-γ production and its actions on melanoma cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465 · cited 2×
“In contrast, the actions of endogenously produced IFN- have been shown to play a key role in tumor immunosurveillance and can prevent the development of tumors in susceptible mice via its ability to enhance tumor immunogenicity (25).”
BackgroundInterferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor
Schindler, C., Shuai, K., Prezioso, V. R., & Darnell, J. E. (1992) · Science · doi:10.1126/science.1496401 · Cited by 899
Cited by
Complex modulation of cell type-specific signaling in response to type I interferons
van Boxel-Dezaire, A. H. H., Rani, M. R. S., & Stark, G. R. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.014 · Cited by 530
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
Zaki, M. H., Vogel, P., Body-Malapel, M., Lamkanfi, M., & Kanneganti, T.-D. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002046 · Cited by 411
IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells
McMichael, E. L., Jaime-Ramirez, A. C., Guenterberg, K. D., Luedke, E., Atwal, L. S., Campbell, A. R., Hu, Z., Tatum, A. S., Kondadasula, S. V., Mo, X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0004 · Cited by 70
Self-citation
Metadata
- Authors
- Lesinski, G. B., Badgwell, B., Zimmerer, J., Crespin, T., Hu, Y., Abood, G., & Carson, W. E.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06
- Volume
- 172
- Issue
- 12
- Pages
- 7368-7376
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1582258347
- Cited by
- 29
- References
- 2
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.